North America Vascular Graft Market

North America Vascular Graft Market Size (2023 to 2028)

The vascular graft market size in North America is forecasted to hike at a promising CAGR from 2023 to 2028.

The expansion of the vascular grafts market in the North American region is expected to be fuelled by rising cases of vascular illnesses, excessive blood sugar, hypertension, and other risk factors that lead to blood vessel blockage. Other complimenting factors that drive market expansion over the forecast period include an increasing geriatric population, technological advancements, and lifestyle changes (consumption of junk food, tobacco, and alcohol).

In addition, every year, 525,00 Americans are predicted to have a heart attack, with 210,000 already suffering from cardiovascular diseases. Therefore, the market is expected to be favored by the rising expenses per capita income. The market is further driven by the individuals who become more conscious of peripheral artery disease and coronary artery disease and the expanding acquisition of vascular grafts in existing countries. Furthermore, owing to flexible regulatory rules and an increase in the burden of aneurysms, the market is likely to rise significantly in the coming years.

The need for vascular grafts is projected to rise in the North American region as the requirement for hemodialysis grows. In addition, the rising number of patients with end-stage renal disease, together with the growing number of patients with chronic kidney disease, will result in a rise in dialysis procedures throughout the region.

Additionally, through intensive research and development initiatives, prominent market players are launching innovative and enhanced vascular grafts—for example, W.L. Gore and Associates announced the launch of the VBX stent graft for the treatment of restenosis lesions in iliac arteries. This graft was created with EPTFE stent graft technology and comes in a variety of sizes to meet the demands of patients.

Treatment techniques are expensive, and reimbursement policies for prosthetic grafts are poor, which is estimated to hamper the market's growth rate. In addition, patients may experience severe or even incurable problems resulting from product failure, which is also expected to impede the market’s growth rate.

This research report on the North American vascular graft market has been segmented & sub-segmented into the following categories:

By Product: 

• Peripheral Vascular Graft  
• Endovascular Aneurysm Repair Stent Grafts
  • Abdominal Aortic Aneurysm (AAA)
  • Thoracic Aortic Aneurysm (TAA)
• Hemodialysis Access Graft

By Raw Material: 

• Biosynthetic
• Polyester
• Polyurethane (PU)
• Polytetrafluoroethylene (PTFE)

By End-User: 

• Ambulatory Surgical Centers
• Hospitals

By Application: 

• Coronary Artery Disease
• Aneurysm
• Vascular Occlusion
• Renal Failure
• Others

By Country;

• The United States
• Canada
• Rest of North America

Geographically, the North American vascular graft market is predicted to dominate the global market during the forecast period. The market growth is attributed to the high prevalence of diabetes, cardiovascular disease, and chronic kidney disease in North America; the region retained its dominant position. Furthermore, devices or products using cutting-edge technology are being introduced to address the clinical demand for off-shelf small-diameter vascular grafts with higher quality properties, which is expected to drive market expansion.

The United States vascular graft market is estimated to play a significant role in the North American market from 2022 to 2027. During the forecast period, the market for vascular grafts in the United States is expected to grow at a CAGR of 5.4%. The market growth is contributed by reimbursement methods, improved healthcare infrastructure availability, and technological advancement in the healthcare sector. Furthermore, healthcare costs in the United States are substantial, with the country spending $315 billion per year on cardiovascular disease management.

From 2022 to 2027, the Canadian vascular graft market is predicted to rise at a significant rate. According to the World Health Organization (WHO), Canada's healthcare spending increased from $4,529.36 in 2014 to $4,718.30 in 2016.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the North American vascular graft treatment market profiled in this report are Endologix Inc., LeMaitre Vascular, Inc., MAQUET Holding B.V.B. Braun Melsungen AG, & Co. KG, Medtronic plc, C. R. Bard, Inc., Cardinal Health Inc., Cook Medical Inc., Terumo Corporation, and W. L. Gore & Associates, Inc.